Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company ...

Leerink analyst Marc Goodman downgraded Opthea (OPT) to Market Perform from Outperform.Light Up your Portfolio with Spark:Easily identify ...

Leerink Partners initiated coverage on shares of Medpace (NASDAQ:MEDP – Free Report) in a research note released on Monday morning, Marketbeat.com reports. The brokerage issued a market perform rating ...

Research analysts at Leerink Partnrs dropped their FY2028 EPS estimates for ARS Pharmaceuticals in a research note issued to ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire David Einhorn. In this article, we are going ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome ...

Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary ...

CorMedix (NASDAQ: CRMD) Q4 2024 Earnings Call Mar 25, 2025, 8:30 a.m. ET Good day, and welcome to the CorMedix Inc.

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...

The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...

Q4 2024 Management View CEO Joe Todisco highlighted the commercial success of DefenCath, noting net revenue of $31.2 million for Q4 and $43.5 million for the full year 2024. He emphasized that the ...